Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
406B | 48.1% | 72.3% | 42.8% | 175 | 11.7% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
180B | 82.0% | 70.9% | 56.5% | 25.9 | 10.5% |
| GILD Gilead Sciences |
Biotechnology
HIV, COVID-19, Hepatitis, Oncology |
156B | 81.8% | 60.7% | 65.7% | 19.5 | 16.4% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Gene Therapy |
119B | 86.3% | - | 33.6% | 32.4 | -5.32% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
83.1B | 74.5% | 14.9% | 48.5% | 18.8 | -8.04% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
52.9B | 61.7% | - | 34.9% | - | 44.2% |
| ARGX argenx |
Biotechnology
FcgRn-Blocker, MusK-Agonist |
52.2B | 70.9% | - | 50.7% | 35.9 | 14.9% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Cold-Relief |
45.1B | 69.5% | 53.1% | 38.0% | 22.5 | -7.58% |
| INSM Insmed |
Biotechnology
Liposomal Antibiotic, DPP1 |
37.9B | 35.9% | - | 51.8% | - | 111% |
| ONC BeiGene |
Biotechnology
BTK Inhibitor, PD-1 Antibody, PARP |
33.6B | 64.6% | - | 28.9% | 584 | 39.9% |
| NTRA Natera |
Biotechnology
Panorama, Horizon, Vistara |
32.8B | 48.0% | - | 71.8% | - | 20.9% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis, Spinal |
26.0B | 64.5% | - | 32.9% | 16.2 | -0.58% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Orenitram, Unituxin |
22.9B | 87.8% | - | 51.9% | 19.2 | 14.6% |
| BNTX BioNTech SE |
Biotechnology
Cancer Immunotherapies |
22.9B | 13.2% | 1.0% | -39.4% | - | -30.0% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, Immunotherapies |
22.1B | 11.0% | 1.0% | -42.1% | - | -39.3% |
| GMAB Genmab AS |
Biotechnology
Antibody Therapies, Oncological |
20.9B | 78.2% | - | 30.3% | 14.8 | 24.3% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
19.7B | 89.2% | - | 53.2% | 17.0 | 20.4% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
15.7B | 28.4% | - | 75.8% | - | 53.4% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
15.6B | 32.1% | - | 80.2% | - | 52.2% |
| BIM Biomerieux |
Biotechnology
Diagnostic, Instruments, Reagents |
15.3B | 78.0% | 53.4% | -16.5% | 34.7 | -8.31% |
| BBIO BridgeBio Pharma |
Biotechnology
TTR Stabilizer, FGFR Inhibitor |
14.7B | 45.0% | - | 86.5% | - | 130% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine |
14.5B | 84.4% | - | 18.1% | 34.8 | -12.8% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, Liver Therapy, MASH |
13.6B | 57.1% | - | 72.6% | - | 57.3% |
| SMMT Summit Therapeutics |
Biotechnology
Antibody, Immunotherapy, Oncology |
13.0B | 43.2% | - | -17.4% | - | -19.2% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone |
13.0B | 36.4% | - | 60.4% | - | 30.9% |
| IONS Ionis |
Biotechnology
Triglyceride, Amyloidosis, SMA |
13.0B | 22.0% | 0.21% | 66.1% | - | 93.2% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
12.9B | 69.8% | 11.7% | 30.4% | 27.4 | 9.64% |
| MRNA Moderna |
Biotechnology
Vaccines, Oncology, Rare-Diseases |
12.2B | 22.6% | - | -20.1% | - | -40.5% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
11.9B | 91.9% | - | 67.6% | 18.5 | 9.43% |
| BMRN Biomarin |
Biotechnology
Enzyme, Replacement, Therapy |
11.3B | 84.3% | - | -39.4% | 21.9 | -24.3% |
| RNA Avidity Biosciences |
Biotechnology
Antibody-Oligonucleotide |
10.9B | 33.0% | - | 75.2% | - | 96.0% |
| RGC Regencell |
Biotechnology
TCM Formulations, Neurocognitive |
10.4B | 37.0% | - | 44.1% | - | -15.3% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
9.70B | 49.2% | - | 69.1% | - | 186% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 39.9% | - | 95.0% | - | 1,468% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.18B | 31.9% | - | 96.2% | - | 1,301% |
| HALO Halozyme |
Biotechnology
Enzyme, Cancer, Immunodeficiency |
7.96B | 89.6% | - | 38.0% | 14.3 | 18.8% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Skeletal |
7.85B | 38.2% | - | 56.1% | - | 10.0% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
7.69B | 31.0% | - | 62.4% | - | 6.56% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin |
7.65B | 65.2% | 20.5% | 23.3% | 13.8 | 6.82% |
| RYTM Rhythm |
Biotechnology
Setmelanotide, Rare Obesity, MC4R |
7.49B | 42.2% | - | 51.4% | - | 51.0% |
| MRUS Merus BV |
Biotechnology
Bispecific Antibodies, BIZENGRI |
7.35B | 30.2% | - | 68.1% | - | 78.7% |
| KRYS Krystal Biotech |
Biotechnology
Gene, Therapy, Topical, Wound, Skin |
7.29B | 88.5% | - | 78.6% | 37.7 | 33.5% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
6.95B | 23.5% | - | 67.6% | - | 586% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
6.87B | 33.2% | - | 60.3% | - | 214% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
6.65B | 31.4% | - | 70.3% | - | 61.3% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
6.24B | 30.0% | - | 3.15% | - | -53.1% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.10B | 65.7% | - | 63.0% | 8.83 | 40.3% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
5.82B | 49.5% | - | 69.8% | - | 286% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
5.81B | 34.2% | - | 66.0% | - | 109% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.55B | 64.0% | - | 72.8% | 135 | 89.9% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene-Edited Cell Therapy, CAR T |
5.40B | 32.5% | - | 29.7% | - | 7.26% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
5.34B | 36.4% | - | 82.7% | - | 35.7% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
5.27B | 29.5% | - | 25.1% | - | -14.5% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
4.92B | 33.8% | - | 59.7% | - | 109% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, BTK |
4.89B | 67.1% | - | -9.69% | 11.1 | -18.7% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.75B | 28.6% | - | 64.0% | - | 544% |
| ACAD ACADIA |
Biotechnology
Antipsychotic, Rett |
4.72B | 86.1% | - | 57.9% | 18.0 | 21.3% |
| ADMA ADMA Biologics |
Biotechnology
IVIG, Immune Globulin, Hepatitis |
4.66B | 84.3% | - | 14.8% | 22.7 | -14.0% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.62B | 26.1% | - | 24.8% | - | -23.5% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.59B | 89.2% | - | -25.5% | 13.8 | -17.5% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.52B | 74.0% | 2.63% | 68.6% | 36.9 | 143% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
4.49B | 26.5% | - | 12.1% | - | -15.5% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
4.41B | 51.8% | - | 63.1% | - | 29.6% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, Oncology, Myeloma |
4.16B | 29.3% | - | -53.4% | - | -47.0% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
4.12B | 42.4% | - | 23.3% | - | -27.5% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
4.08B | 47.4% | - | 65.1% | - | 59.2% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
4.04B | 27.9% | - | 57.4% | - | 14.5% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
3.88B | 49.6% | 0.14% | 58.2% | 86.9 | 47.8% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
3.77B | 38.9% | - | -13.1% | - | -29.8% |
| CNTA Centessa |
Biotechnology
OX2R Agonist, Neurological Drugs |
3.75B | 33.5% | - | 52.8% | - | 21.1% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
3.71B | 27.0% | 3.50% | 64.1% | - | 1.69% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.55B | 27.6% | - | 60.8% | - | 70.7% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.50B | 41.9% | - | 65.0% | - | 69.0% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.48B | 30.4% | - | 45.3% | - | -5.45% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.36B | 63.3% | - | 32.9% | 112 | -11.8% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
3.34B | 40.1% | - | 68.0% | - | 305% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
3.34B | 36.8% | - | -35.1% | - | -52.6% |
| DYN Dyne Therapeutics |
Biotechnology
Antisense Oligos, FORCE Platform |
3.30B | 31.5% | - | 12.8% | - | -34.9% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
3.26B | 39.1% | - | 83.9% | - | 193% |
| CGON CG Oncology |
Biotechnology
Oncolytic Virus, Immunotherapy |
3.24B | 32.0% | - | 45.7% | - | 21.5% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.22B | 66.8% | - | 57.5% | 94.4 | 75.3% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
3.18B | 75.9% | - | -25.5% | 69.9 | -35.8% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
3.13B | 23.3% | - | 73.3% | - | 16.4% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
3.08B | 47.2% | - | 70.8% | - | 33.5% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
3.01B | 89.6% | - | 25.5% | 14.3 | -8.10% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
2.96B | 30.7% | - | 44.1% | - | 151% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
2.96B | 35.5% | - | 35.3% | - | 7.75% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immunotherapy |
2.86B | 33.3% | - | 71.7% | - | 33.5% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.86B | 28.1% | - | -5.92% | - | -4.90% |
| EWTX Edgewise |
Biotechnology
EDG-5506, EDG-7500, Oral |
2.79B | 30.5% | - | 9.82% | - | -22.2% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Tablet, Rare |
2.64B | 42.2% | - | -22.7% | - | -14.2% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, eIF2B Activator |
2.63B | 25.6% | - | -15.3% | - | -32.9% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.56B | 30.0% | - | 49.3% | - | 16.4% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor, ADC |
2.46B | 46.7% | - | 77.9% | - | 72.9% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.29B | 33.3% | - | -62.2% | - | -51.9% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.25B | 30.3% | - | -43.3% | - | -85.3% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136 |
2.20B | 35.4% | - | 79.0% | - | 280% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.17B | 38.2% | - | 30.2% | - | -0.67% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.16B | 25.8% | - | -11.2% | - | -13.6% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.15B | 93.4% | - | 81.1% | 29.1 | 54.1% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.11B | 66.2% | - | -61.9% | - | -34.7% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology |
2.05B | 31.9% | - | -71.3% | - | -39.8% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
2.03B | 29.9% | - | 70.5% | - | 51.0% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.96B | 37.1% | - | 61.3% | - | 101% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
1.94B | 36.2% | - | -6.48% | - | -40.7% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 36.5% | - | 8.23% | - | -25.8% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, CBL-B Inhibitor |
1.93B | 35.8% | - | 11.9% | - | -17.6% |
| ZBIO Zenas BioPharma |
Biotechnology
Obexelimab, ZB002, ZB004, ZB001 |
1.91B | 31.4% | - | 80.6% | 2.61 | 241% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
1.90B | 62.3% | - | -9.99% | 144 | -44.6% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF Biopolymer, Anti-Il6 |
1.90B | 47.6% | - | 87.0% | - | 175% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.85B | 27.0% | - | 77.5% | - | 50.5% |
| IMCR Immunocore Holdings |
Biotechnology
Immunotherapy, Oncology, Melanoma |
1.85B | 40.7% | - | 26.8% | - | -1.37% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.83B | 39.2% | - | 40.1% | - | 26.4% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense, Oligonucleotide |
1.81B | 73.3% | - | 62.0% | 46.7 | 139% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.81B | 37.2% | - | 32.5% | - | 1.03% |
| CLDX Celldex |
Biotechnology
Antibody, Monoclonal, Bispecific |
1.78B | 40.4% | - | 18.4% | - | -10.8% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.72B | 37.2% | - | -61.1% | 24.0 | -67.0% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
1.70B | 35.7% | - | -38.2% | - | -27.6% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.68B | 24.4% | - | 78.4% | - | 26.8% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.62B | 47.0% | - | 75.5% | - | 152% |
| BCRX BioCryst |
Biotechnology
Antiviral, Hae, Complement, Protein |
1.61B | 72.2% | - | -24.5% | - | -15.6% |
| CAPR Capricor |
Biotechnology
Cell Therapy, Exosome Vaccine |
1.57B | 28.6% | - | 63.8% | - | 63.5% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 63.6% | - | 5.59% | 50.7 | -27.2% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.55B | 38.4% | - | 17.2% | - | 12.3% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.50B | 29.3% | 1.0% | 63.6% | - | 28.6% |
| MEDCL Medincell |
Biotechnology
Antipsychotic, Analgesic |
1.49B | 57.7% | - | 34.0% | - | 21.7% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.49B | 38.0% | - | 28.2% | - | 117% |
| RLAY Relay Therapeutics |
Biotechnology
RLY-2608, RLY-4008, RLY-8161 |
1.47B | 47.8% | - | 43.6% | - | 66.7% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.46B | 33.3% | - | 25.1% | - | -3.51% |
| MBX MBX Biosciences |
Biotechnology
Peptide Prodrug, GLP-1 Antagonist |
1.44B | 32.8% | - | 84.2% | 4.19 | 46.5% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.43B | 32.5% | - | -61.3% | - | -74.3% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
1.42B | 66.4% | - | 33.6% | 540 | 363% |
| IMTX Immatics |
Biotechnology
TCR Bispecifics, ACT Cell |
1.41B | 21.7% | - | 53.0% | - | 19.9% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.41B | 34.0% | 87.6% | -9.34% | 54.9 | -14.8% |
| ANAB AnaptysBio |
Biotechnology
Rosnilimab, ANB032, ANB033 |
1.40B | 25.3% | - | 84.1% | - | 207% |
| TYRA Tyra Biosciences |
Biotechnology
FGFR, Precision, Platform |
1.39B | 29.9% | - | 82.0% | - | 54.4% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 51.4% | - | 228% |
| SVRA Savara |
Biotechnology
Molgramostim, Inhaled Therapy |
1.30B | 23.0% | - | 80.3% | - | 66.4% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Trial, Anxiety |
1.30B | 32.0% | - | 67.6% | - | 50.5% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.1% | - | 75.5% | - | 41.1% |
| PVLA Palvella |
Biotechnology
Rapamycin Gel, Rare Dermatology |
1.25B | 25.6% | - | 86.5% | - | 639% |
| SANA Sana Biotechnology |
Biotechnology
Islet Cell Therapy, CAR-T Cell |
1.21B | 35.3% | - | 52.2% | - | 109% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.20B | 25.5% | - | 25.1% | - | -0.05% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, CNS TYK2 |
1.19B | 50.9% | - | 20.0% | - | 0.61% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.18B | 66.8% | - | 50.4% | - | 25.9% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitors, Brain-Penetrant |
1.17B | 34.2% | - | 68.6% | - | 140% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Esophagus |
1.17B | 53.8% | - | 50.1% | - | 17.6% |
| GLUE Monte Rosa |
Biotechnology
MGD Pipeline, MRT-2359, MRT-6160 |
1.15B | 71.5% | - | 73.9% | 55.1 | 86.9% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
1.14B | 42.7% | - | -4.14% | - | -70.3% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
1.13B | 29.5% | - | 10.8% | - | -7.82% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.13B | 39.8% | - | -31.7% | 3.45 | -33.6% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle Radiotherapy |
1.12B | 36.3% | - | 55.5% | - | 438% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticle-Based Radiotherapy |
1.12B | 49.3% | - | 58.1% | - | 576% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.11B | 16.4% | - | -27.0% | - | -4.36% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.11B | 33.3% | - | -45.2% | - | -37.7% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.10B | 48.5% | - | 59.6% | - | 85.5% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Bispecific |
1.09B | 14.5% | - | -1.73% | - | -45.5% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
1.04B | 49.9% | - | 13.5% | 15.2 | -25.8% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.03B | 21.3% | - | -34.2% | - | -26.4% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
1.02B | 86.1% | - | -21.4% | 25.6 | -38.2% |
| CVAC CureVac |
Biotechnology
Mrna, Vaccines, Oncology |
1.02B | 26.6% | - | 0.84% | 6.75 | 11.0% |
| BBOT BridgeBio Oncology |
Biotechnology
KRAS Inhibitor, HER2 Therapy |
1.01B | 47.6% | - | 40.5% | - | 15.4% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-007, ERAS-601 |
1.00B | 35.4% | - | 42.7% | - | 16.8% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
986M | 31.5% | - | -8.22% | - | -37.9% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
982M | 27.9% | - | 34.8% | - | 120% |
| MLTX MoonLake |
Biotechnology
Nanobody, IL-17A, IL-17F |
980M | 28.4% | - | -14.8% | - | -79.2% |
| 5CV CureVac |
Biotechnology
Vaccines, Oncology, mRNA, Printer |
970M | 27.2% | - | -21.2% | 6.35 | -13.0% |
| ESPR Esperion |
Biotechnology
Bempedoic Acid, Ezetimibe |
936M | 55.8% | - | 34.9% | - | 42.5% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
922M | 29.8% | - | 1.53% | 3.13 | -15.7% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapy, PD-L1 Inhibitor, HBV |
921M | 29.9% | - | 78.0% | - | 23.9% |
| CMPX Compass |
Biotechnology
Bispecific Antibodies, Checkpoint |
914M | 32.6% | - | 66.1% | - | 225% |
| KURA Kura Oncology |
Biotechnology
Ziftomenib, Tipifarnib, KO-2806 |
904M | 56.2% | - | 24.8% | - | 1.43% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
894M | 27.3% | - | -29.3% | - | -68.9% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
861M | 39.9% | - | -25.8% | - | -78.0% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, Tgf-Beta |
844M | 46.2% | - | 26.4% | - | 58.4% |
| VIR Vir Biotechnology |
Biotechnology
Antibodies, Vaccines, T-Cell |
835M | 29.6% | - | -16.7% | - | -29.7% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
831M | 40.1% | - | -4.41% | - | -37.9% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
821M | 34.7% | - | -21.3% | - | -16.1% |
| RIGL Rigel |
Biotechnology
Kinase Inhibitor, Blood Disorder |
810M | 92.8% | - | 70.5% | 7.21 | 110% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002 |
796M | 36.0% | - | 45.5% | - | 171% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
793M | 25.6% | - | 23.7% | - | 36.1% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
791M | 32.7% | - | -28.0% | - | -34.4% |
| DBVT DBV Technologies |
Biotechnology
Peanut Allergy Patch, Milk Allergy |
771M | 38.3% | - | 63.9% | - | 400% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor, Oral |
767M | 39.7% | - | 59.6% | - | 54.5% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
750M | 33.8% | - | 45.4% | - | 26.2% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment, Oral |
748M | 36.7% | - | 27.3% | - | -22.7% |
| ORGO Organogenesis |
Biotechnology
Allografts, Skin-Substitutes |
745M | 31.8% | - | 64.2% | - | 44.9% |
| ATXS Astria Therapeutics |
Biotechnology
Navenibart, STAR-0310, Monoclonal |
741M | 36.2% | - | 34.7% | - | 23.7% |
| VLA Valneva SE |
Biotechnology
Vaccines, Chikungunya, Lyme, Zika |
732M | 25.4% | - | 5.90% | - | 36.5% |
| RGNX Regenxbio |
Biotechnology
Gene Therapy, Retinal Diseases |
732M | 14.7% | - | 64.0% | - | 55.3% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
722M | 60.5% | - | 81.9% | 14.2 | 241% |
| GYRE Gyre Therapeutics |
Biotechnology
Pirfenidone, Hydronidone, F573 |
699M | 61.9% | 1.0% | -19.8% | 182 | -50.2% |
| LYEL Lyell Immunopharma |
Biotechnology
CAR-T, Dual-Target, Solid Tumor |
671M | 22.3% | - | 35.2% | - | 102% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapy, Ocular |
666M | 38.8% | - | 26.0% | - | 7.44% |
| EBS Emergent |
Biotechnology
Opioid Overdose Nasal Spray |
663M | 52.0% | 0.13% | 48.4% | 9.42 | 1.98% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Autologous Renal |
662M | 41.8% | - | -21.2% | - | 9.72% |
| DRUG Bright Minds |
Biotechnology
Serotonin Agonists, Epilepsy |
659M | 27.8% | - | 80.5% | - | 60.9% |
| KROS Keros Therapeutics |
Biotechnology
KER-050, KER-012, KER-065 |
651M | 74.4% | - | 38.8% | 13.7 | 8.37% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editor |
644M | 40.6% | - | -25.4% | - | -1.66% |
| ENGN enGene Holdings |
Biotechnology
Bladder Cancer Gene Therapy |
636M | 29.4% | - | 53.7% | - | 10.7% |